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Abstract
Prostate cancer has been considered a disease of elderly men, and thus historically less focus
has been on prostate cancer research than many other cancer types. However, as life expectancy
is increasing all over the world, more life years are lost when men are diagnosed with prostate
cancer at the age of 70 years now than before. Therefore, it is increasingly important to improve
the diagnostic pathway of prostate cancer in modern health care. My thesis aims to address
some of the issues in the current prostate cancer diagnostic pipeline using risk prediction mod-
els.
Measuring the level of prostate-specific antigen (PSA) in blood is widely used as a blood test to
screen for prostate cancer and evidence has shown that mortality decreases with PSA testing.
However, because PSA testing has a high false-positive rate, many unnecessary biopsies are per-
formed on healthy men and many men are overdiagnosed with indolent disease (International
Society of Urological Pathology (ISUP) grade group 1). In Study I the objective was to predict
the risk of clinically consequential cancer (ISUP ≥ 2) at biopsy and the cumulative probability
of having a negative biopsy when being PSA tested with one, two, three, four, or five to eight
year intervals. We found that men with a PSA level above 1 ng/mL had an increased risk of
ISUP ≥ 2 prostate cancer when screened with longer then annual intervals, while men with a
PSA level below 1 ng/mL had low risk of ISUP ≥ 2 prostate cancer regardless of time between
testing. The benefit of a shorter screening interval needs to be balanced with the increased
cumulative probability of having a negative biopsy which we found to be twofold for annual
vs. biennial testing intervals and threefold for annual vs. triennial testing intervals.
Knowledge about the relationship between PSA, age and different grades of prostate cancer is
important for clinicians working with prostate cancer diagnosis because of how widely used the
PSA test is. In Study II we studied the association between the risk of indolent and clinically
consequential prostate cancer (ISUP 1 and ISUP ≥ 2) and PSA and age, respectively. Our study
cohort comprised of 6.083 biopsied men from the STHLM3 study and 72.996 biopsy cores from
those men. In the overall ISUP grade system, lower grades can be masked by higher grades,
and thus we studied the associations for both overall ISUP grade and for ISUP grade on each
biopsy core. Our results showed that ISUP 1 prostate cancer was not significantly associated
with PSA or age, on overall ISUP grade or on individual biopsy core level. In contrast, our
results showed that ISUP ≥ 2 prostate cancer is significantly associated with increasing PSA
level and older age. Our results indicate that PSA leakage of ISUP 1 prostate cancer cells is
more similar to that of benign prostate tissue than ISUP ≥ 2 prostate cancer tissue.
The use of magnetic resonance imaging (MRI) before biopsy to diagnose prostate cancer has
increased in current clinical practice. Combining results from prostate MRI with existing risk
prediction models can improve the predictive abilities of the models. The aim of Study III
was to develop a risk prediction model (S3M-MRI), combining the Stockholm3 score and the
PI-RADS (Prostate Imaging Reporting and data System) score from MRI to predict the risk of
ISUP≥ 2 prostate cancer. We developed the S3M-MRI model using data from the STHLM3-MRI
diagnostic study and compared the model performance of the S3M-MRI to the Stockholm3
model and PI-RADS score. We also compared five diagnostic strategies for clinical outcomes.
We found that the combined S3M-MRI model had better predictive abilities than both the
Stockholm3 and the PI-RADS alone. However, when we compared it to different clinical strate-
gies, the sequential use of the Stockholm3 test followed by MRI on Stockholm3 positive men
resulted in similar numbers of performed biopsies and diagnosed ISUP ≥ 2 prostate cancers
while saving many MRI scans.
Prostate cancer diagnosis is based on the result of the prostate biopsy and reclassification
of ISUP grade on radical prostatectomy samples compared to biopsy is common. In Study IV
our aim was to study what effect reclassification of disease status based on prostate biopsies
has on the performance of prostate cancer risk prediction models using simulations and data
from the STHLM3 Radical Prostatectomy Cohort. The cohort comprised of 780 men from the
STHLM3 study who were diagnosed with prostate cancer and treated with a radical prostatec-
tomy between 2013 and 2015. We compared four simulated prediction model scenarios with
and without error in disease status and calculated the area under the receiver operating charac-
teristics (ROC) curve (AUC) of the Stockholm3 score for predicting clinically significant prostate
cancer assessed using biopsy and radical prostatectomy samples. Our simulations showed that
fitting a risk prediction model using data with error in the disease status only leads to a small
decline in the true predictive performance, but leads to a large decline in apparent predictive
performance when evaluated against data with error in the disease status. Moreover, our results
showed that the Stockholm3 test has stronger association with clinically significant prostate
cancer defined on prostatectomy samples (without errors) than on biopsy samples (with errors).
In conclusion, in this thesis we have aimed to describe a part of the risk associated with diag-
nosis of prostate cancer as well as developing new prostate cancer risk prediction models. This
thesis contributes to the constant pursue of improving the current prostate cancer diagnostic
pipeline in order to improve the lives of men screened for or diagnosed with prostate cancer.
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Chapter 1
Introduction
Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive
system, and it is highly prevalent in older men. Prostate cancer testing and diagnosis is con-
troversial, and in most developed countries unorganized prostate cancer testing using a blood
test called the Prostate-Specific Antigen (PSA) test is very common. The test is an inefficient
screening test with many false positive results. The widespread use of the PSA test results in
biopsying many healthy men (around half of all biopsies are benign) and overdiagnosis of
indolent cancer that can result in overtreatment, infections and anxiety for the men involved.
Thus improved methods for prostate cancer testing are in great need in health care systems
around the world.
My supervisors have previously developed a prostate cancer risk prediction model called the
Stockholm3 test. It was developed in the STHLM3 study, a large cohort study including 59.149
men aged 50–69 years without prostate cancer living in Stockholm, Sweden. The test is based
on a risk prediction model using blood based biomarkers, clinical variables and a genetic score
to predict the risk of high-grade prostate cancer.
In my thesis I have mainly focused on continuing to improve, validate and further develop the
Stockholm3 test, as well as analyzing and describing current PSA testing and prostate cancer
risk in Stockholm, Sweden.
Chapter 2
Aims of the thesis
Ineffective screening methods and insufficient risk stratification of screened men are
common issues in the current prostate cancer diagnostic pipeline. My thesis aims to
describe and address these using risk prediction models.
More specifically, the aims are:
• To study the benefits (decreased risk of higher ISUP grade cancer at diagnosis)
and harms (increased risk of having a negative biopsy) of having PSA tests with
one, two, three, four or five to eight years testing intervals given a man’s current
PSA level, age, and family history of prostate cancer.
• To study the associations between the risk of ISUP 1 and ISUP≥ 2 prostate cancer
and PSA and age, respectively.
• To develop a risk prediction model (S3M-MRI) that combines the Stockholm3
test and PI-RADS scores from magnetic resonance imaging (MRI) of the prostate
to predict the risk of high-grade prostate cancer.
• To study what effect reclassification of ISUP grade between prostate biopsy and
radical prostatectomy specimens has on the predictive performance of prostate
cancer risk prediction models using simulations and data from the STHLM3 Rad-
ical Prostatectomy Cohort.
Chapter 3
Background
3.1 Prostate Cancer Incidence and Mortality
Prostate cancer is the second most common cancer in the world among men, with
an estimated 1.3 million men diagnosed with the disease in 2018. Incidence varies
between regions, but it is the most common cancer in men in developed countries
[1], where almost 70% of the total number of cases worldwide occur. Highest rates
are reported in Australia/New Zealand, North America and Europe, where the use of
prostate-specific antigen (PSA) testing and subsequent biopsy has become widespread
[2]. In Sweden, the incidence rate of prostate cancer has increased substantially since
the introduction of PSA testing for screening of prostate cancer [3]. In 1970, the inci-
dence rate of prostate cancer was 71 new cases per 100,000 men and incidence rose
steadily in the following twenty years to 113 new cases per 100,000 men in 1990.
After the introduction of PSA testing in 1987, and gradual usage increase during the
early 1990s, there was a rapid reported increase in the incidence rate in Sweden. This
increase reached a peak in 2004, when 224 new cases were detected per 100,000 men
(Figure 3.1). Since 2004, the age-standardized incidence rate has decreased slightly,
although prostate cancer was still the most common cancer reported among men in
Sweden in 2017 [3, 4].
Among cancers, prostate cancer is the fifth leading cause of death in men in the world,
with an estimated 360,000 deaths from prostate cancer in 2018 (around 4% of all
cancer deaths in that year). Mortality rates of prostate cancer across developed re-
gions do not differ as widely as incidence rates. However, mortality rates are higher
in Southern Africa, the Nordic countries and parts of South America (see Figure 3.2b)
[1, 2]. Worldwide, Sweden has among the highest prostate cancer mortality rates (49.5
per 100,000 men in 2014), making prostate cancer the leading cause of death from
cancer among Swedish men. Despite the rise in incidence in Sweden, the mortality has
decreased since 2005 when it reached a peak of 59 per 100,000 men (Figure 3.1) [3].
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Figure 3.1: Age standardized incidence and mortality rates for prostate cancer in Sweden per 100.000
men. Data from Socialstyrelsen (www.socialstyrelsen.se, accessed 20.02.2019) [3]
Unlike many other cancer types, prostate cancer incidence and mortality rates are
not closely associated. Data from the World Health Organization (WHO) reveals that
incidence rate is highest in more developed countries like North America, Australia and
Europe (Figure 3.2a), while mortality rate (Figure 3.2b) is highest in Southern Africa.
Frequent PSA testing in more developed countries that detect a high rate of low-risk
prostate cancers and a higher prostate cancer mortality rate among African-American
men are the most plausible reasons for this disparity in incidence and mortality rates
around the world.
3.2 Current Prostate Cancer Diagnostic Strategy
The most common way to diagnose prostate cancer is through assessment of PSA lev-
els, either through routine testing or with suspected increased prostate cancer risk. If
the PSA level is elevated, the men are usually recommended to undergo a prostate
biopsy, which is subsequently analysed by a pathologist for prostate cancer assessment.
After diagnosis of prostate cancer, there are several treatment options available. Figure
3.3 shows an overview of the most common current prostate cancer diagnostic pipeline.
3.2.1 The Prostate-Specific Antigen (PSA) Test and Testing Intervals
As described above, the PSA test is commonly used to test for prostate cancer in de-
veloped countries. This development can be explained by greater access to the test,
more knowledge among older men of prostate cancer and PSA and better access to
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(b) Mortality rates of prostate cancer
Figure 3.2: Incidence and mortality rates of prostate cancer in the world in 2018. Data from World
Health Organization [1]
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Figure 3.3: The most common prostate cancer diagnosis begins with a PSA blood test, followed by a
10-12 core systematic prostate biopsy. The biopsy sample is then graded by a pathologist and given an
ISUP grade and if diagnosed with prostate cancer, the men have an option of different treatments.
health care [5]. Evidence linking PSA testing to reductions in prostate cancer specific
mortality are controversial. Many studies have shown that PSA testing leads to reduced
prostate cancer specific mortality rates [6, 7, 8], while results from Andriole et al. in
the PLCO Cancer Screening Trial showed no effect of PSA screening on the rate of
death from prostate cancer [9]. However, those results can be at least partly explained
with the study design, as a large proportion of the men in the control group were also
PSA tested while the study was ongoing and that most men entering the study had
already been previously tested. With the high false-positive rate of the PSA test, its
wide usage leads to many unnecessary prostate biopsies and overdiagnosis of indolent
cancers, resulting in overtreatment [10, 11, 12].
Previous prostate cancer screening trials have used PSA testing intervals of two or
four years. However, since these trials were not conducted in a randomized manner
with different intervals as a primary objective, little evidence exists supporting an ideal
screening interval. Van Leeuwen et al. examined screening intervals in a study using
data from the European Randomized Study of Screening for Prostate Cancer (ERSPC),
and estimated a 43% reduction in the diagnosis of advanced prostate cancer for screen-
ing with 2 year intervals (Gothenburg) compared to 4 year intervals (Rotterdam) [13].
In the Gothenburg arm, the incidence of low-grade prostate cancer was 46% higher
than in Rotterdam, indicating overdiagnosis of prostate cancer. Modelling studies that
have compared screening men annually vs. biennially showed a reduction in the risk
of a false-positive test by up to 50% and overdiagnosis by up to 30% while preventing
about 80% of deaths prevented with annual screening [14].
Because the ideal PSA screening interval is controversial, the recommendations on
testing intervals differ between organizations. The American Cancer Society (ACS)
recommendion states that men over 50 years with a PSA below 2.5 ng/mL should
be tested biennially, and men with a PSA 2.5 ng/mL or higher should be tested annu-
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ally [15]. The American Urological Association (AUA) recommendation is that men
aged 55–69 should be tested biennially [16], and the National Comprehensive Cancer
Network (NCCN) recommends 2–4 year intervals for men with PSA below 1 ng/mL
aged 45–74 and 1–2 year intervals for men with PSA of 1 ng/mL or higher [17]. The
European Association of Urology (EAU) recommends PSA testing every 2 years for
men at risk, and up to 8 years for men with low risk [18]. Some of these organizations
also state in their guidelines that this area of research needs more evidence to find the
optimal PSA testing interval. In 2017, the US Preventive Services Task Force (USPSTF)
recommended in a draft statement to offer PSA testing to men aged 55 to 69 after indi-
vidualized decision making – after advocating against PSA testing altogether in 2012
[19, 20]. They give no recommendation for a specific testing interval and mention that
more research on the subject is needed.
3.2.2 Diagnosis
Prostate cancer is most commonly diagnosed with biopsies of the prostate, while a
small fraction of the men are diagnosed with fine-needle aspiration from the prostate,
resected material from transurethral resection of the prostate (TUR-P), or by symptoms.
The median age of diagnosis in Sweden has decreased over the years from 74 years
in 1996 to 70 years in 2005 (due to the introduction of PSA testing in asymptomatic
men) [21]. Below I will briefly describe the systematic biopsy procedure – currently
the most commonly used biopsy procedure – as well as the variables associated with
prostate cancer prognosis, of which the most important is the Gleason grade.
Systematic Biopsy
Prostate biopsies are recommended for men with an increased risk of prostate cancer
due to relevant risk factors, which include elevated PSA levels, abnormal digital rectal
exam, older age, family history of prostate cancer, ethnicity (African-American), comor-
bidity, and symptoms. The diagnosis of prostate cancer is established with histological
evaluation of prostate tissue. The systematic biopsy of the prostate under transrectal
ultrasound guidance (TRUS) was introduced in 1989, when 6 biopsy cores were taken
from the base, middle and apical region of the prostate [22]. Since the procedure
was developed, modifications have been instituted to extract a greater number of sam-
ples. For example, because prostate cancer is more prevalent in the peripheral zone of
the prostate, modern procedures obtain more biopsies from the lateral region of the
prostate. Currently, the most common method in Sweden is to sample 10 to 12 biopsy
cores from the prostate according to a systematic pattern [23, 24, 25]. Traditionally,
an ultrasound device has been used to guide the physician to direct the needle in the
areas of the prostate that need to be sampled. This method is widely used today even
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though it exhibits low specificity and low sensitivity in the detection of high-grade
prostate cancer.
The Gleason Grading System
To evaluate the prognosis of prostate cancer from a prostate biopsy, a microscopic eval-
uation of the tissue has to be made. The International Society of Urologic Pathology
(ISUP) modified Gleason grading system is used to grade prostate biopsies, and reflects
the pattern of gland formation and differentiation level of the cells in the prostate (Fig-
ure 3.4) [26, 27, 28]. In Figure 3.4 we see that lower Gleason grades are associated by
small, tightly packed glands while the cells spread out with higher grades and the glan-
dular architecture loosens [29]. By definition, a total Gleason score is calculated from
two diagnostic outcomes (numbers ranging from 3 to 5). The first number is based on
the microscopic appearance of the most prevalent graded cell pattern, and the second
number is based on the next most prevalent graded cell pattern in the biopsy sample.
However, the highest grade needs to be included as either of the two numbers. These
numbers are then combined to produce the total Gleason grade and from this, the
ISUP grade is produced, resulting in a value between 1 to 5. ISUP grade 1 is equivalent
to Gleason score 3+3, ISUP 2 is equivalent to Gleason 3+4, ISUP 3 is equivalent to
Gleason 4+3, ISUP 4 is equivalent to Gleason 4+4 and ISUP 5 is equivalent to Gleason
4+5 or higher. Cancers with a higher ISUP grade are more aggressive and have a worse
prognosis, indicating higher risk and greater mortality [30, 31, 32].
Gleason score 3+3=6 (Gleason 6), which equals the ISUP grade 1, is the most common
prostate cancer diagnosis. According to a cohort study by the National Institutes of
Health (NIH), a large proportion (around 50%) of the men diagnosed with prostate
cancer in countries with high PSA testing have tumors that have a very low level of
metastatic potential (ISUP 1 prostate cancer) [33]. Our research group has observed
similar numbers in the Stockholm PSA and Biopsy Registry Database, which includes
men diagnosed with prostate cancer in the Stockholm area. Such tumors are unlikely to
become metastatic, and mortality rates of men with ISUP 1 prostate cancer are similar
to that of men without a prostate cancer diagnosis [34, 35]. Furthermore, in a large
American study, Ross et.al showed that ISUP 1 prostate cancer is not associated with a
metastatic phenotype [36]. Even so, ISUP 1 prostate cancer meets the histological defi-
nition of cancer and can affect the patients and cause them considerable psychological
stress [37, 38]. Thus, the debate remains whether ISUP 1 prostate cancer should be
considered prostate cancer and whether it meets the molecular and genetic criteria for
cancer [10, 11, 39, 40].
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Figure 3.4: Gleason grade. Lower grades are associated with small, closely packed glands. Cells spread
out and lose glandular architecture as grade increases [29].
Prostate cancer with ISUP grade 2 or higher is generally a more aggressive type of
cancer and has been associated with worse prognosis and higher mortality rates than
ISUP 1 prostate cancer [41]. Tumor cells with a higher ISUP grade accumulate in poorly
formed glands that are less specificly seperated from the stroma (see Figure 3.4) [29].
The disrupted cell membrane of the tumor cells thus leaks PSA from the prostate into
the bloodstream, and therefore the level of PSA is often used to test for prostate cancer.
However, it is relevant to note that men with a high-grade prostate cancer normally
have high PSA levels while some men with only slightly elevated PSA levels can have
very aggressive prostate cancer, but not all men with high PSA levels have prostate
cancer.
Prognostic Risk Stratification Systems
There are several prognosis risk stratification systems following prostate cancer diag-
nosis. According to the Swedish national guidelines, the risk (severity) of the prostate
cancer is divided into four categories depending on T-stage, Gleason grade, PSA level
and mm cancer in biopsy (see Table 3.1) [42].
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Table 3.1: Classification of prostate cancer risk after diagnosis from the Swedish national guidelines
[42]
Risk Definition Treatment Options
Very low
T1c, Gleason ≤ 6, PSA density <
0,15, < 8 mm in ≤ 4 out of 8-12
biopsy cores
Appropriate for active surveillance
Low
T1-T2a, Gleason ≤ 6, PSA < 10
ng/mL
Appropriate for active surveillance
Intermediate
T2b, Gleason = 7, 10 ≤ PSA ≤ 19
ng/mL
May benefit from intervention
High
T2c-T3, Gleason > 7 or extensive
Gleason = 3+4, PSA ≥ 20 ng/mL Benefit from intervention
Reclassification of ISUP Grade
The reclassification of ISUP grade from systematic biopsy to whole gland pathology on
prostatectomy samples is very common and it can have serious consequences for the
patient if the diagnosis is erroneous. Reclassification happens for two primary reasons:
the biopsy needle can miss the area in the prostate with the highest ISUP grade, and
the pathologist grading the whole prostate can disagree with the pathologist grading
the biopsy sample (concordance between pathologists on the same biopsy sample is
around 30–50% [43]). These classification problems are very common with systematic
biopsies, and studies have shown that overall agreement of the ISUP grade when
comparing biopsy sample and radical prostatectomy sample from the same individual
is only around 35–60% [44, 45, 46].
3.2.3 Initial Treatment
Prostate cancer treatment is a large topic and the focus of an enormous body of research.
Here I will only give a very brief and general overview of available treatment options,
since it has not been a focus of my research. Currently, there are several options for
treatment after prostate cancer diagnosis. Common clinical practice recommendations
for men with very low or low risk prostate cancer is active surveillance with no active
treatment of the disease. If there is evidence that the cancer is progressing, treatment
with curative intent might be recommended [42, 47]. For men with over 10 years ex-
pected lifespan and intermediate risk prostate cancer, either radiation or prostatectomy
are typically recommended. For men with high risk prostate cancer, either radiation or
chemotherapy is commonly recommended, except for men with a metastatic disease,
for which androgen suppression treatment is recommended (see Table 3.1) [42, 18].
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Active Surveillance
Prostate cancer is a disease with a broad span of prognosis and the typically recom-
mended treatment option for men with ISUP 1 prostate cancer is active surveillance,
where the patient is actively followed for signs of disease development rather than
intervention. Active surveillance includes repeated PSA testing, MRI and biopsies. If
the diagnosis remains static, the men are not actively treated for prostate cancer.
Radical Prostatectomy and Radiation
Men diagnosed with intermediate or high-risk localized prostate cancer without metas-
tases and over 10 years expected lifespan are generally recommended to have a radical
prostatectomy or radiation of the prostate [18]. Radical prostatectomy is the surgical
removal of the whole prostate gland and the seminal vesicles. The procedure can be
performed as an open, laparoscopic or robot-assisted laparoscopic surgery. The surgery
has risks and complications following the procedure, with the most common including
infections, internal bleeding, erectile dysfunction and urinary incontinence [18]. Ra-
diation of the prostate is also used to treat men with intermediate/high-risk prostate
cancer. During this procedure, high-energy radiation beams are aimed at the prostate
gland with the goal of destroying the cancerous cells while sparing as much of the
normal surrounding tissue as possible [48].
3.3 Improvements in the Prostate Cancer Diagnostic Strategy
The current prostate cancer diagnostic strategy, which includes PSA testing and system-
atic biopsy analysis for opportunistic screening and diagnosis of prostate cancer, has
been shown in many studies to reduce prostate cancer mortality [6, 7, 8]. However,
both the PSA test as well as systematic biopsies have demonstrated poor sensitivity
and specificity [49, 50], resulting in overdiagnosis, overtreatment, and misdiagnosis
of cancer [6, 11, 12, 45]. Therefore, current research focuses on systematically inves-
tigating and evaluating a new clinical workflow to screen for and diagnose prostate
cancer using risk prediction models, magnetic resonance imaging (MRI) along with
targeted biopsy and automated image analysis of biopsy samples (see Figure 3.5).
This improved diagnostic pipeline can improve both sensitivity to diagnose high-grade
prostate cancer and reduce unintended consequences of screening, e.g. false positive
biopsy recommendations, overdiagnosis, and overtreatment.
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Figure 3.5: One option for improvement in the prostate cancer diagnostic chain starts with a Stockholm3
test, followed by MRI of the prostate and a targeted biopsy. AI assisted technology is then used to grade
the biopsy samples with ISUP grade in order to save workload and harmonize ISUP grading. Men with
aggressive cancers would then have genomic profiling of the cancerous tissue for individual treatment
options. Men with a negative test in the chain will have an individualized follow-up with next generation
patient management system.
3.3.1 Prostate Cancer Risk Prediction Models and the Stockholm3 Test
To improve prostate cancer diagnostics, risk prediction models have been developed
to systematically recommend men to undergo a prostate biopsy. These models, e.g.
Stockholm3, PCPTRC, PBCG, ERSPCRC, 4K, and PHI have shown favourable results
compared to the PSA test to detect high-grade prostate cancer [51, 52, 53, 54, 55, 56,
57, 58]. These models have been shown to reduce the number of performed biopsies
and decrease detection of ISUP 1 prostate cancer, while being able to detect ISUP ≥ 2
prostate cancer with similar sensitivity.
The STHLM3 study was a prospective, population-based, paired, screen-positive study
in men aged 50–69 years without previously diagnosed prostate cancer, which utilizes
the Stockholm3 risk prediction model. The Stockholm3 risk prediction model includes
a combination of biomarkers (PSA, free PSA, intact PSA, hK2, MSMB, MIC1), genetic
polymorphisms (232 SNPs), and clinical variables (age, family history, previous prostate
biopsy, prostate exam) to predict the risk of ISUP ≥ 2 prostate cancer. The STHLM3
study consisted of a training (n=11,130) and a validation cohort (n=47,688) of men
living in Stockholm County, Sweden. To fit the Stockholm3 model, clinical and genetic
data from the training cohort was analysed, which was subsequently evaluated against
the validation cohort. All men with a PSA of 1 ng/mL or higher were tested with the
Stockholm3 test. The men with a PSA above 3 ng/mL or a Stockholm3 test score above
10% were referred to undergo prostate biopsy. In the study, 7,417 men underwent
biopsy, and of those, 1,241 men were diagnosed with ISUP ≥ 2 prostate cancer. The
Stockholm3 model performed significantly better in predicting the risk of ISUP ≥ 2
prostate cancer, reducing the number of biopsies by 32% and avoiding 44% of benign
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biopsies compared to using a PSA test for referral to biopsy at the same sensitivity for
ISUP ≥ 2 prostate cancer. Additionally, the study showed that by using the Stockholm3
test, the number of cancers with ISUP grade 1 could be reduced by 17% by more pre-
cisely predicting the risk of high-grade prostate cancer and thus recommending fewer
healthy men to undergo biopsy [51]. Thus, the study provided supporting evidence
that using a good risk prediction model in addition to PSA testing, can better forecast
the probability of ISUP ≥ 2 prostate cancer.
3.3.2 Magnetic Resonance Imaging (MRI) of the Prostate and Targeted Biopsy
Over the last few years, magnetic resonance imaging (MRI) of the prostate has been
introduced as part of the clinical assessment of prostate cancer. MRI has the poten-
tial to identify areas of the prostate where prostate cancer is likely to reside. Then,
using the targeted biopsy, the MRI of the prostate is fused into an ultrasound device,
thereby directing the physician toward areas in the prostate where a suspicion of can-
cer exists. Other available methods are cognitive fusion biopsy or in-bore biopsy. The
targeted biopsy method is anticipated to overcome shortcomings of the existing sys-
tematic biopsy method, which is performed without precise knowledge of the location
of a suspicious lesion. For the reporting of MRI findings, the Prostate Imaging Report-
ing and Data System (PI-RADS) score has been developed. The score is based on a
value from 1 to 5 (given for each lesion), with 1 being most probably benign and 5
being highly suspicious of malignancy [59]. Studies using MRI and targeted biopsies
have shown improved diagnostic accuracy of ISUP ≥ 2 prostate cancer, while decreas-
ing both the detection of ISUP 1 prostate cancers and number of performed biopsies
[49, 60, 61, 62, 63].
In a new study by Grönberg et al., the Stockholm3-MRI phase 1 study, they combined
the Stockholm3 test and MRI targeted biopsies and compared it to current diagnos-
tic methods. The two primary outcomes were the number of performed biopsies and
the ISUP-specific number of diagnosed cancers. The results showed that by using a
combination of the Stockholm3 test and targeted biopsy, there was a significant 42%
reduction in the number of performed biopsies and 46% reduction in the number
of diagnosed ISUP 1 prostate cancers, while detecting the same number of ISUP ≥
2 prostate cancers. Thus markedly improving the diagnostic specificity compared to
current practice [62].
3.3.3 Automated Image Analysis of Prostate Biopsy Samples
The possible next step in improving the prostate cancer diagnostic pipeline is to use
artificial intelligence for the improvement of image analysis of ISUP grading of prostate
biopsy samples. Currently there is a severe shortage of uro-pathologists well trained in
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grading biopsy samples, which might result in the earlier mentioned variability between
pathologists on the same biopsy sample (reclassification of ISUP grade). With a more
objective evaluation of biopsy samples, using artificial intelligence assisted prostate
cancer pathology these negative effects can be reduced. The aim is to reduce the
variability in pathology assessment, increase throughput of analysis (shorten waiting
time for patient diagnosis) and to improve prediction of the correct disease status of
prostate cancer compared to current pathology procedures.
Chapter 4
Data Material
In this thesis, I have used three data sets: the observational Stockholm PSA and Biopsy
Registry, data from the prospective and population based STHLM3 diagnostic trial, and
data from the Stockholm3-MRI phase 1 study.
4.1 The Stockholm PSA and Biopsy Registry
In Study I we used data from the Stockholm PSA and Prostate Biopsy Registry, which
links PSA, biopsy and prostate cancer diagnosis data in Stockholm, Sweden. Infor-
mation on PSA tests was collected from the three clinical chemistry laboratories that
performed all PSA tests in Stockholm, from 2003 to 2015. Data on prostate biopsies
were collected from three pathology departments in Stockholm and family history of
prostate cancer was obtained from the Swedish Multi-generation Register. By linking
to the Regional Prostate Cancer Register and the Swedish National Cancer Register we
obtained data on tumor stage, Gleason score, and mode of detection (PSA detected
or symptomatic detection). On November 23, 2015, the Stockholm PSA and Biopsy
Registry included data from 448,000 men and 1.8 million PSA tests. The study was
approved by the local ethics review board. One of the strengths of my thesis is hav-
ing access to this data set since it is a unique registry describing the PSA testing and
biopsies in a whole region with around 2 million inhabitants. Like all registry data, the
data set has its limitations, with data that has to be cleaned and may contain some
registration errors.
4.2 The STHLM3 Cohort
The STHLM3 study was a prospective and population-based diagnostic study includ-
ing 59,149 men aged 50–69 years without prostate cancer, randomly invited from the
Swedish Population Register. In total 7,417 men were biopsied. The STHLM3 dataset is
unique, including information of a combination of plasma protein biomarkers, genetic
markers, and clinical variables on all participants including detailed biopsy information
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as well as a prostate exam (digital rectal exam and prostate volume) on the men who
were biopsied. We used data from the STHLM3 cohort in Study II and IV.
Currently, 780 men in the STHLM3 cohort have had a radical prostatectomy as a treat-
ment for high-risk prostate cancer. We have collected extensive pathology information
on those men and compiled the STHLM3 Radical Prostatectomy Cohort. The data was
used in Study IV of my thesis.
The limitations of the study are that so far there is limited follow-up time, and most of
the men in the study were of Northern European descent. Currently there are ongoing
validation studies to broaden the scope and generalize the use of the Stockholm3 test.
4.3 The Stockholm3-MRI Phase 1 Cohort
In Study III we used data from the Stockholm3-MRI Phase 1 study, which was a prospec-
tive, multi-center, paired diagnostic study [64]. Patients were recruited between 1st
of May 2016 to 1st of June 2017 from three sites: Stockholm, Sweden and Oslo and
Tønsberg, Norway. Men aged 45–75 years without a previous prostate cancer diagnosis
and referred to the sites for a prostate cancer diagnostic workup (prostate biopsy or
pre-biopsy MRI) were eligible for inclusion (see Figure 4.1).
Figure 4.1: Diagnostic strategies for the detection of prostate cancer in the Stockholm3-MRI phase 1
study [62].
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In total, 532 men participated in the study and they all underwent blood sampling,
MRI and a combined systematic/MRI targeted biopsy procedure depending on the
MRI result. The main goal of the study was to compare the performance of MRI-TRUS
fusion targeted biopsy and/or systematic biopsy with and without the requirement of a
prior positive Stockholm3 test. This study investigated an important link in the future
prostate cancer diagnostic chain, and one of its strengths is combining the information
from the Stockholm3 test with the results from MRI and targeted biopsies.
Chapter 5
Methods - Prediction Models in Medicine
Prediction models are becoming increasingly important in our society and personal
lives. Their purpose can range from predicting the risk of a disease in health care
to predicting the risk of a person recommitting a crime in the judicial system. These
models are most often used in the background without our knowledge and they can
be very important for the development of great improvements as well as harmful and
discriminating if used unfairly.
Within the field of medicine, the use of prediction models is increasing. They can
be effective in predicting the risk of a disease in order to decide if additional testing
is needed. If the risk of a disease is low, additional invasive tests can be avoided but
when the risk is high, further diagnostic workup can be necessary for the patient. The
ideal would be to have a disease status test that predicts with perfect accuracy the true
disease status of the patient. However, no such tests are available and precise tests are
often invasive and can cause side effects that should be avoided if possible (such as
biopsy or surgery to determine cancerous tissue). Thus less invasive risk prediction
models are needed to aid physicians in their decision of an invasive intervention to
determine disease status.
Examples of the use of prediction models in medicine are early detection of a dis-
ease (a blood based, urine based or radiology based screening test), automating the
process of image analysis for medical purposes and individualized treatment based
on a person’s genetics, environment and lifestyle. The current era of evidence based
medicine requires the development of more advanced techniques and methods to indi-
vidualize the whole diagnostic chain based on each person’s attributes, from screening
to diagnosis and treatment.
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5.1 Model Development
5.1.1 Statistical Models for Prediction
The first step of the risk prediction model development is the model selection. The
model we select to represent our data in our risk prediction model, has to be based
on the type of data we have and the type of outcome we want to predict the risk for.
The outcome we want to predict can be continuous, binary, categorical, or ordered
categorical and we will have to choose different models for each type of outcome.
For prediction of continuous variables, the most commonly used model is the lin-
ear regression model where the parameters of the model are selected by the principle
of least squares; minimizing the sum of the squares of the differences between the
observed dependent variable and those predicted by the model.
To predict the risk of binary variables in medical outcomes, the logistic regression
model is very useful, especially for diseased and non-diseased outcomes. It models a
binary outcome variable using the logistic function and is used to test for potential
associations between a set of given variables and a binary or categorical outcome, as
well as predicting the risk of the outcome variable based on one or more predictors.
In a logistic regression, we use the logistic link function to restrict the predictions be-
tween 0 and 1. The model is the linear function of the logistic transformation of the
probability p of the outcome y or P(y = 1) using the logistic function:
logit(p) = log(odds(p)) = log(
p
1− p ) = α+ βi x i (5.1)
where α is the intercept, βi are the estimated regression coefficients and x i are the
predictors. The most common way to estimate the coefficients is using the maximum
likelihood method, but other less used methods are available. The interpretation of the
β coefficients is the same as with other regression models. It indicates the difference
in the log-odds for a one unit increase in its predictor holding all other predictors in
the model constant. The odds ratio is calculated as the exponent of the βi coefficients.
The predicted probability p is calculated by:
p(y = 1) =
e(α+βi x i)
1+ e(α+βi x i)
=
1
1+ e−(α+βi x i) (5.2)
The maximum likelihood method can be used to optimize the logistic model, i.e. to
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find the most likely value of the model’s parameters given the data. The log-likelihood
is used because it is computationally easier to maximize than the likelihood. It is cal-
culated as the sum over all subjects of the distance between the natural log of the
predicted probability p for the binary outcome to the actually observed outcome y
[65]:
LL =
N∑
j=1
y j · log(p j) + (1− y j) · log(1− p j) (5.3)
where y is the binary outcome variable and p is the predicted probability for each
subject for the outcome.
From equation 5.1 we can calculate the odds ratio (OR) comparing the odds of y = 1
when x = 1 to when x = 0:
OR =
odds(x + 1)
odds(x)
=
exp(α+ β(x + 1))
exp(α+ β x)
= exp(β) (5.4)
There are multiple other models available to derive predictions for binary outcome
variables. These are for example neural networks, regression tree and support vector
machine.
In Study I and II a multinomial, multivariable logistic regression was used to pre-
dict the risk of three different outcomes of biopsy: benign, ISUP 1 prostate cancer and
ISUP ≥ 2 prostate cancer. The outcome variable is a categorical variable and takes
three different values. For predictor x , each response level follows a logistic regression
model for x , specifying a selected level as the reference. Thus for level j of the outcome
compared to reference level s of the outcome, the model is:
log

P(y = j)
P(y = s)

= α+ βi x i (5.5)
Thus, βi is the log odds ratio comparing the odds of outcome y = j to the odds of
y = s for a unit increase in x i [66].
Ordinal outcomes are also quite common in medical studies and to predict those
types of outcomes we can use the proportional odds logistic regression model. In this
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extension of the logistic regression model, we assume a common set of regression
coefficients across all levels of the outcome and intercepts are estimated for each level.
5.1.2 Overfitting and Underfitting in Prediction Models
When developing a good prediction model, a primary interest should be the model’s
performance in prediction of data outside the sample study. One of the issues in the
development of prediction models is called overfitting, i.e. the predictions fit the data
well in our sample study, but the model does not predict well on new data outside the
study sample. Overfitting causes optimism in the evaluation of our model’s performance
and it can bee seen as the apparent performance on our data sample compared to the
true performance of the model when evaluated on a population sample. Optimism of
a prediction model is defined as the difference between the apparent performance and
the true performance (see equation 5.6) [65].
Optimism = Apparent per f ormance− True per f ormance (5.6)
When comparing prediction models, the model’s optimism is one measure we can use
for comparison. Models with higher optimism are possibly overfitting the data and can
be improved.
When the complexity of our models is not capturing important distinctions and patterns
in our data that results in a high prediction error in our training and validation data
as well as external data it is called underfitting. To solve the problem of underfitting,
adding more features to our model is effective. Thus, to find the optimal model, we
need to keep midlevel complexity in the models to minimize both underfitting and
overfitting (see Figure 5.1). Methods such as bootstrapping and cross-validation are
available to help us quantify and decrease overfitting in our models.
5.1.3 Ensemble Modeling
Ensemble modeling is a statistical learning method that uses several different models
to improve the stability and predictive performance of our prediction model, either
by using different types of models or different training data sets. Below I will briefly
describe two ensemble modeling methods, stacking and boosting.
Stacking
For the purpose of improving the Stockholm3 predictions in Study IV, using two dif-
ferent logistic models, one model trained on the biopsy data and one model trained
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Figure 5.1: Optimal models minimize underfitting and overfitting. Overfitting increases with model
complexity while underfitting decreases.
on the prostatectomy data, we explored a method called stacking, which combines
many different models to improve the predictions. For a set of models m = 1, 2, ..., M
and given predictions fˆ1(x), fˆ2(x), ..., fˆM(x) for those models, fˆ −im (x) is the predic-
tion at x , using model m of M models, with the ith training observation removed.
We obtain the stacking estimate of the weights from the logistic regression of yi on
fˆ −im (x i), m = 1, 2,3, ..., M . Stacking weights are then given by:
wˆst = argmin
w
N∑
i=1

yi −
M∑
m=1
wm fˆ
−i
m (x i)
2
(5.7)
which gives us the final predictions:
∑
m wˆ
st
m fˆm(x) [67]. The method did not increase
the performance of our prediction model in study IV and thus the results of the analysis
are not presented in the paper.
Boosting
The main principle of boosting algorithms for prediction models is to fit a sequence of
models to weighted versions of the data. A boosted classifier is in the form:
FT (x) =
T∑
t=1
ft(x) (5.8)
where each ft(x) is a weak learner that takes x as input and returns a value that is the
predicted class of the specific weak learner. One example of a boosting method is the
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AdaBoost algorithm introduced by Freund and Schapire [68] in 1996. In the AdaBoost
algorithm, the examples that were misclassified in the subsequent classifiers are given
more weight so that the weak learner is forced to focus on the hard examples in the
training set [69]. Then the predictions are combined with a weighted classification to
produce a final prediction. The boosting method did not improve our predictions in
the Stockholm3 model and thus the results of the analysis were not presented in Study
IV.
5.2 Internal Model Validation
When choosing the best model to use for our data we need to have two goals in mind;
first, the model selection and second, the model assessment: When we have chosen a
model and its parameters, we need to estimate its prediction error on new data. If we
have a large data set to address both issues it is optimal to divide the data sets into
three: a training set, a validation set, and a test set. The training set is used to train the
model; the validation set is used to estimate the prediction error for model selection
and finally we use the test set to assess the generalization error of the chosen model.
Optimally a test set should be set aside before the analysis begins and then only used
once at the end of the data analysis for validating the selected model. The methods
available for model validation are e.g. apparent validation, split-sample validation,
cross-validation and bootstrapping. As cross-validation and bootstrapping are the most
widely used I will describe them in more detail.
K -fold Cross-validation
In a data sparse situation, which is often the case with clinical data, it is not optimal to
remove big parts of the data for validation and testing of the model. Then K-fold cross-
validation, an internal validation technique, is very useful to estimate the expected
prediction error. It can be used to evaluate how well the risk prediction model will
work in practice on an external data set using the same data set used to train the model
as well as to decrease overfitting of the data.
To handle the scarce data problem, in K-fold cross-validation we use a part of the
available data to fit the model and another part to test it [67]. The data is split into
K different data sets of similar size (see Figure 5.2 where K = 5). Then the model
is trained on the other K − 1 data sets (the blue boxes) and the prediction error is
estimated on the kth part (the red box). This is repeated for k = 1,2,3, ..., K and to
produce the cross-validation estimate of the prediction error, the K error estimates are
accumulated over all K folds.
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Figure 5.2: K-fold cross-validation: Total data set is divided into K parts of equal size, K − 1 parts are
used to train the model which is then tested on part k of the data to estimate prediction error in our
model.
Bootstrapping
Bootstrapping is a method that relies on random sampling with replacement. The word
bootstrapping comes from the phrase to pull oneself up by one’s bootstrap based on a
German tale of the notorious Baron Münchhausen who was famous for the exaggerated
tales of his own adventures. According to the tale, he was able to pull himself out of
a swamp by his own hair. In a later version of this story, he used the bootstraps of his
shoes to pull himself out of the sea [70]. However, in statistics, the Baron does not
pull himself up by his bootstraps but the word is used for a method to estimate the
sampling distribution of an estimator by resampling with replacement [71](similar to
the Baron’s achievements but maybe not as unbelievable as his hair pulling!). Contrary
to the tale, the method is widely applicable and can provide valuable insight for statis-
tical inference to deduce the probability distribution of a population.
The method works as follows: With a total sample size of n, we draw with replacement
a sample size m from n (typically m = n) called the bootstrap sample. We repeat this
procedure many times (often a few thousand) and then we calculate a statistic that
we are interested in for each bootstrap sample to estimate the variance. The bootstrap
theory can be used to make computerized calculations of basic statistical concepts, like
e.g. confidence intervals [71].
Bootstrapping can also be used to quantify the optimism (Equation 5.6) of a pre-
diction model [72] as well as to calculate the optimism-corrected performance [65].
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With a bootstrap variant, a model is repeatedly fitted in bootstrap samples, and then
the performance is evaluated in the original sample. To estimate the optimism, we use
the bootstrap:
Optimism = Bootst rap per f ormance− Test per f ormance (5.9)
Then we can calculate the Optimism–corrected performance:
Optimism−cor rected per f ormance = Apparent per f ormance in sample − Optimism
(5.10)
5.3 Model Evaluation
The predictive abilities of clinical risk prediction models are important to evaluate. The
most common and recommended statistical tools to evaluate these predictive abilities
evaluate discrimination, calibration and clinical relevance of the models.
5.3.1 Discrimination
Discrimination evaluates how well the predicted risk from the model distinguishes
between patients with and without disease. The most commonly used measure for
discrimination is the concordance (c)-statistic and for a binary outcome model the
c-statistic is the area under the receiver operating characteristic (ROC) curve (AUC). It
is based on the specificity and sensitivity of our model to predict the risk of disease and
plots of the sensitivity vs. specificity for different cutoff thresholds for the probability
of the disease predicted by our risk prediction model.
Sensitivity is the number of true positive predictions divided by the number of those
with the disease (see Equation 5.11) and the specificity is the number of true negative
predictions divided by the people without the disease (see Equation 5.12). To classify
a patient as having the disease, we have to choose a threshold and if the predicted risk
exceeds that threshold, the patient is classified as having the disease. If the predicted
risk is below that threshold, the patient is classified as not having the disease. The
ROC curve is a plot of the sensitivity vs. specificity over the whole range of thresholds
from 0% to 100% (see an example of a ROC curve of a prediction model in Figure 5.3
showing the sensitivity and specificity for 4 different cutoff thresholds).
Sensi t ivi t y = T P/ndisease (5.11)
Speci f ici t y = T N/nnotdiseased (5.12)
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A risk prediction model with a ROC curve that has an AUC close to 1 is a very good
prediction model, meaning that the model almost perfectly discriminates between
individuals with and without the disease, while a model with an AUC close to 0.5 is
no better than randomly assigning the individuals into healthy and diseased groups.
We can interpret the AUC as the probability that a random patient with the outcome is
given higher probability of the outcome by the model than a randomly chosen patient
without the outcome [65].
Figure 5.3: Example of a ROC curve of a clinical risk prediction model, the S3M-MRI model developed
in Study III. This ROC curve has an AUC of 0.884 and points on the ROC curve represent the specificity
and sensitivity for 4 different cutoff thresholds in our model.
5.3.2 Calibration
Calibration Plot
The calibration of prediction models evaluates the agreement between the predicted
risks from the model and observed values in the data. Thus, if we predict that a patient
has a 10% risk of prostate cancer, the observed frequency of prostate cancer should
be 10 out of 100 patients with the same covariate values of the one on which the risk
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was predicted [65]. Calibration assessments include calibration plots, where we plot
the predicted values on the x-axis and observed outcomes on the y-axis. For regression
models, this is a scatter plot, while for logistic regression models when the outcomes
are 0 and 1 this is not possible. To estimate the observed probabilities relative to the
predicted probabilities we can us a smoothing technique (such as loess, kernels or bin
smoothing).
Figure 5.4: Examples of calibration plots for two clinical risk prediction models, with predicted risks on
the x-axis and observed outcomes on the y-axis.
Figure 5.4 shows examples of calibration plots for two prediction models. The plots
show both the observed outcomes (black dots) and the smoothed estimated outcomes
(the blue line) for the observed probabilities of a clinical risk prediction model with
a binary outcome. The observed outcomes lie at y = 0 and y = 1. When a model is
perfectly calibrated (observed probabilities match exactly the predicted probabilities)
then the blue line follows the 45° red line. In Figure 5.4, the model to the left is better
calibrated than the model to the right. When we plot the calibration for a model on
the data that we used to develop the model, that is the apparent calibration, because
in model development, the average of the outcomes is the average of the predictions
(Mean(Y ) = Mean(Yˆ )) [65]. Applying the model to external data can result in worse
calibration.
Calibration-in-the-large
Calibration-in-the-large and Calibration slope are two calibration measures that can
be used to estimate how well a prediction model is calibrated on external data and to
compare the model to other existing prediction models. Calibration-in-the-large is the
difference between the mean of the predictions (Yˆ ) and the mean of the observations
(Ynew):
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Calibration− in− the− lar ge = Mean(Ynew)−Mean(Yˆ ) (5.13)
This applies for calibration of linear regression models and we can test the difference
in the means with a one-sample t-test [65]. For calibration of logistic regression models
we can make a comparison with an odds ratio:
OR =
odds(Mean(Yˆ ))
odds(Mean(Ynew))
=
Mean(Yˆ )
1−Mean(Yˆ )
Mean(Ynew)
1−Mean(Ynew)
(5.14)
To test the statistical difference in a logistic regression we need to compare logi t(Ynew =
1) to logi t(Yˆ = 1). We can write that:
logi t(Ynew = 1)− logi t(Yˆ ) = a
logi t(Ynew = 1) = a + logi t(Yˆ ) = a + o f f set(l inearpredic tor)
(5.15)
We can test statistical significance of the intercept being equal to zero vs. being not
equal to zero with a Wald test or likelihood ratio (LR) test.
Then we estimate the calibration slope from the recalibration model:
logi t(Ynew = 1) = a + boveral l ∗ logi t(Yˆ ) = a + boveral l ∗ l inearpredic tor (5.16)
The miscalibration of the model (the deviation of the slope from 1) can be tested by:
logi t(Ynew = 1) = a + bmiscal ibration ∗ l inearpredic tor + o f f set(l inearpredic tor)
(5.17)
The bmiscal ibration is the slope coefficient and its deviation from 1 can be tested with a
Wald test or LR test.
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Goodness-of-fit Tests
To test the calibration of a prediction model with binary outcomes, the Hosmer-Lemeshow
(H-L) test has been used [73]. Goodness-of-fit of a prediction model is the ability of
the model to fit a given set of data. Specifically the H-L test calculates if the predicted
probabilities match the observed probabilities in population subgroups of our data.
The test has shown to have several limitations, e.g. it only tests for overall calibration
error and not for any particular lack of fit like quadratic effects and it does not properly
take overfitting into account [74]. Therefore, the test is usually not recommended and
I have not used it in my studies to test for calibration.
5.3.3 Decision Curve Analysis
Discrimination and calibration are very important features for evaluating the predic-
tive performance of clinical prediction models. However, when comparing two models,
one can have better discrimination and the other better calibration. So how do we
decide which model is a better clinical prediction model? Decision curve analysis was
developed to overcome these limitations of available evaluation methods. Vickers et al.
introduced the method to calculate the net benefit (NB) of a prediction model as the
key part of the decision curve analysis (DCA) [75].
Net benefit of a prediction model is defined as:
NB =
TruePosi t ives
n
− FalsePosi t ives
n
∗ pt
1− pt (5.18)
where pt is the probability threshold for declaring a patient positive on the test, True−
Posi t ives is the number of patients with the disease at threshold pt , FalsePosi t ives is
the number of patients predicted positive at threshold pt that do not have the disease,
and n is the total number of patients. This number can be thought of as net profit, or
income minus expenditure [76].
It is important to evaluate the net benefit over a range of thresholds pt since there is
no one correct threshold for prediction models. Further, to interpret the NB we need
to compare the NB of a prediction model with two default strategies, where we "treat
all" or "treat none". Treat none always has NB equal to zero and treat all is evaluated
at reasonable values of pt . For pt above prevalence, treat all has a lower NB than treat
none and for pt below prevalence the treat all has a higher NB than treat none. For a
model to be clinically beneficial it has to have higher NB than treat all and treat none
[76].
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Figure 5.5 is an example of a decision curve analysis where NB is plotted for two
prediction models against different thresholds pt from 0 to 0.5. From this analysis we
see that model 2 has a NB above the default strategy to treat all if the risk threshold is
higher than 0.05 while model 1 has a lower NB than treating all from that threshold.
Figure 5.5: Decision curve analysis net benefit curve for two clinical risk prediction models, with net
benefit plotted on the y-axis for different values of the threshold pt on the x-axis.
When a model has a lower NB than any default strategy, the model can be considered
clinically harmful. Well calibrated models can not be harmful while miscalibrated mod-
els can be harmful. An example of that would be a prostate cancer risk model (such
as model 1 in Figure 5.5) which is miscalibrated and predicts the risk of high-grade
prostate cancer too low. Using such a risk prediction model in a clinical setting would
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result in not sending men to biopsy that likely have the disease, and thus it is harmful
for the patient. A model with good discrimination and poor calibration, can be im-
proved by re-calibrating the model to fit external data better. That would result in a
model with higher net benefit then before.
5.3.4 External Validation Studies
When developing clinical prediction models, the model is trained, validated and eval-
uated on patients that are a small sub sample of the total population of patients. The
data we train our models on, most often originates from only one country, with most
patients of the same race and possibly members of a similar gene pool. Then the big
question is: How generalizable is our model in a completely different sub sample of
patients? To be sure that our risk prediction model is good, we need to validate the
model on external data to test the model’s performance on different patients. A model
can do extremely well at predicting the risk of a disease for the same type of patients
in the data the model was trained on, but when exposed to different patients, the
model possibly does not recognize these new predictors and how they are related to
the outcome.
Chapter 6
Results
In summary the main findings of my four studies were:
Study I We observed that men with PSA above 1 ng/mL, have an increased risk of being
diagnosed with ISUP ≥ 2 prostate cancer with longer than annual PSA testing
intervals. However, we also showed that annual PSA testing intervals increase
the cumulative probability of having a negative biopsy compared to biennial and
triennial testing intervals.
Study II We showed that the risk of ISUP 1 prostate cancer is not significantly associ-
ated with PSA and age at time of diagnosis.
Study III A unified S3M-MRI risk prediction model, using the Stockholm3 score and
MRI of the prostate to predict the risk of ISUP ≥ 2 prostate cancer is superior
to the Stockholm3 model and MRI alone. However, the improvement was small
compared to the sequential use of first Stockholm3 and then MRI, which results
in fewer MRI examinations and is simpler from a clinical workflow perspective.
Study IV Reclassifiction of ISUP grade between biopsy and radical prostatectomy speci-
mens has little effect on the true predictive performance of risk prediction models,
but can lead to a large decline in their apparent prective performance.
6.1 Study I
In Study I we analyzed the benefits and harms of different lengths of PSA testing
intervals for men aged 50–74 years. The benefits were decreased risk of ISUP ≥ 2
prostate cancer in biopsy and the harms were increased risk of a false-positive biopsy.
We calculated the risk ratio (RR) of ISUP ≥ 2 and ISUP 1 prostate cancer vs. a benign
outcome at prostate biopsy and the 12-year cumulative probability of having a nega-
tive biopsy by PSA testing intervals, PSA level, age and family history of prostate cancer.
The main analysis showed that men with PSA above 1 ng/mL had increased risk of
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being diagnosed with ISUP ≥ 2 prostate cancer when tested with PSA testing intervals
over 1 year and the RRs ranged from 1.4 to 3.2 depending on testing intervals and
PSA level (see Table 6.1). Our results also showed that men with PSA below 1 ng/mL
were at low risk of being diagnosed with ISUP ≥ 2 prostate cancer irrespective of PSA
testing intervals, only 5% of the men in our study with PSA below 1 were diagnosed
with ISUP ≥ 2 prostate cancer. Age and family history status did not affect the results.
Table 6.1: Risk ratios for ISUP ≥ 2 prostate cancer compared with benign biopsy by pre-index PSA value
and PSA testing intervals using 1-year testing interval as baseline
Outcome PSA value 2 vs 1 yr 3 vs 1 yr 4 vs 1 yr 5-8 vs 1 yr
ISUP ≥ 2 0-1 0.6(0.2 to 1.9) 0.7(0.2 to 3.3) 0.9(0.2 to 4.1) 2.8(1.3 to 6.3)
1-3 1.3(1.1 to 1.7) 1.7(1.3 to 2.2) 1.8(0.2 to 2.4) 2.5(2 to 3.1)
3-5 1.3(1.1 to 1.7) 1.7(1.3 to 2.2) 1.8(0.2 to 2.4) 2.5(2 to 3.1)
5-10 1.4(1.2 to 1.7) 1.2(0.9 to 1.5) 1.7(1.3 to 2.2) 1.6(1.3 to 2.1)
We also calculated the cumulative probability for men without prostate cancer aged
50 and 60 years of having a negative biopsy during 12 years of PSA testing (see Fig-
ure 6.1). We found that with shorter PSA testing intervals, the cumulative probability
of a negative biopsy was twofold when tested annually compared to biennially and
threefold when tested annually compared to triennially. In summary, the cumulative
probability of receiving at least one negative biopsy after 12 years of PSA testing 1)
decreased with longer testing intervals, 2) increased with pre-index PSA level and 3)
was only slightly affected by age and family history of prostate cancer.
6.2 Study II
In Study II, we studied the association of PSA level and age with ISUP 1 and ISUP ≥
2 prostate cancer, respectively. We included 72.996 biopsy cores from 6.083 biopsied
men aged 50–69 years in the STHLM3 study. In the overall ISUP grade, the lower ISUP
grade can be masked by a higher ISUP grade, therefore we studied the associations for
both overall ISUP grade and ISUP grade on each biopsy core. Our results showed that
the risk of ISUP 1 prostate cancer was not significantly associated with PSA level in
biopsy, neither on an overall ISUP grade level nor on a biopsy core level (see predicted
risks in Figure 6.2).
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Figure 6.1: Cumulative probability of a negative biopsy for different PSA testing intervals by age and
PSA level at start of testing and family history status.
Contrary to ISUP 1 prostate cancer, our results showed that the risk of ISUP≥ 2 prostate
cancer was significantly associated with the PSA level. The analysis showed similar
results for the association of the risk of ISUP 1 and ISUP ≥ 2 prostate cancer and
age. There was no statistically significant association between age and ISUP 1 prostate
cancer in contrast to the strong and significant association between age and ISUP ≥ 2
prostate cancer.
6.3 Study III
In Study III we developed a unified prostate cancer risk prediction model (S3M-MRI)
that combined the Stockholm3 score (using biomarkers, clinical variables and a genetic
score) and the PI-RADS score from MRI of the prostate. To develop and test our model,
we used data from the Stockholm3-MRI phase 1 study, including 532 men without
prostate cancer that were referred to a urologist at three sites in Stockholm, Oslo and
Tönsberg between 2016 and 2017. We then compared the predictive abilities of the
S3M-MRI to the Stockholm3 test and PI-RADs score separately with respect to model
discrimination, calibration and net benefit. We then compared clinical outcomes with
five different diagnostic strategies using the three models.
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Figure 6.2: Predicted risk of different ISUP grade prostate cancer from biopsy by PSA and age. Risks are
predicted both on the overall ISUP grade level and the biopsy core level.
Our results showed that the unified S3M-MRI model had superior predictive abilities
compared to the Stockholm3 model and the PI-RADS score to predict the risk of ISUP
≥ 2 prostate cancer. The AUC of the S3M-MRI model was significantly higher than of
the Stockholm3 test and the PI-RADS model. The unified S3M-MRI model also had a
higher net benefit on the decision curve analysis in comparison to the Stockholm3 test
and the PI-RADS model for clinically relevant thresholds for biopsy recommendation.
However, when comparing different diagnostic strategies, using the Stockholm3 test
first followed by MRI for the men that tested positive on the Stockholm3 (Strategy 3
vs. Strategy 4 in Figure 6.3) resulted in a similar number of ISUP 1 prostate cancers
(56 vs. 51) and benign biopsies (64 vs. 69) while detecting similar number of ISUP ≥ 2
cancers (172 vs. 178). Strategy 3 creates a simpler workflow with only one screening
test and much fewer MRI scans than using the S3M-MRI model.
In conclusion, the predictive abilities of the unified S3M-MRI model were superior
to the Stockholm3 model and the PI-RADS score from MRI alone. However, the im-
provement was small compared to using the Stockholm3 test followed by MRI, and
resulted in more MRI scans.
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Figure 6.3: Clinical outcomes of five diagnostic strategies using the Stockholm3 test, MRI and the
S3M-MRI model among 532 men in the Stockholm3-MRI phase 1 study.
6.4 Study IV
In Study IV we investigated the effect of reclassification of ISUP grade (RG) between
prostate biopsy and radical prostatectomy specimens on the predictive performance
of prostate cancer risk prediction models. We calculated the AUC for four simulated
model scenarios with and without error in the disease status (the outcome variable).
Furthermore, we used data from the STHLM3 Radical Prostatectomy Cohort to com-
pute the AUC of the Stockholm3 test to predict significant cancer, defined on biopsy
and prostatectomy samples, respectively.
The results from our simulations showed that fitting a model with error in the out-
come variable leads to a small decline in true predictive performance, but to a large
decline in apparent predictive performance when evaluating the models on data with
error. Simulation of scenario 1 with no error in the outcome variable of our model
(fitting or evaluation) resulted in the highest AUC. Simulation of scenario 2 with error
in the outcome variable in the model fitting, but not in the outcome in the model
evaluation resulted in only a small decline in the AUC compared to scenario 1. On the
other hand, the simulation of scenario 3 and 4, with error in the outcome variable in
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the model evaluation, resulted in a much lower AUC then scenario 1 and 2.
To further illustrate the effect of RG in prostate biopsy, we compared the predictive
performance of a prostate cancer risk prediction model (such as the Stockholm3 model)
to predict clinically significant cancer defined on biopsy (with RG) and radical prosta-
tectomy samples (without RG). We showed with the simulated scenarios that having
error in the outcome variable does not decrease the true predictive performance of
our prediction model. Moreover, our results showed that the Stockholm3 model has
stronger association with clinically significant prostate cancer defined on radical prosta-
tectomy samples (without error) then on biopsy samples (with error).
In conclusion, our results show that RG affects the true predictive abilities a good
prostate cancer risk prediction model only to a small degree and that a model with
good discriminatory performance like the Stockholm3 test discriminates better be-
tween significant and insignificant prostate cancer defined on radical prostatectomy
with fewer errors compared to biopsy with more errors.
Chapter 7
Discussion and Conclusions
7.1 PSA Testing and Risk of Prostate Cancer
From our analysis on the Stockholm PSA and Biopsy registry data in Study I, it was
evident that unorganized PSA testing in Stockholm was very common in spite of no
recommendation for PSA testing by the Swedish National Board of Health and Welfare
[77]. Most recommendations for PSA testing state that it can be beneficial for the men
to start PSA testing at age 50 years and preferably men should not be tested after the age
of 70 or 75 years for healthy men with long life expectancy because the health benefit of
screening after that age would be minimal [15, 16, 78]. Even so, the most tested men in
Stockholm are older (70–79 years old) [79] and in Study I we showed that of the men
tested annually, 56% were 70–74 years old. The current PSA testing pattern has been
an eye opener for health policy makers to accept the fact that unorganized PSA testing
is common and executed poorly since no organized screening program is available for
prostate cancer on a national level. In my opinion, screening in some form would be
beneficial from a public health perspective with better organization, meaning that men
with high risk of being diagnosed with prostate cancer are followed up properly and
men with low risk or less benefit from screening are not overtested. Improved screening
methods are also an important link in the implementation of organized screening, i.e.
risk prediction models such as the Stockholm3 test, PCPTRC, PBCG, ERSPC, 4K or PHI
together with MRI and targeted biopsies [51, 53, 55, 56, 57, 58].
7.1.1 PSA Testing Intervals
If prostate cancer screening is to be implemented in health care systems in some form,
a good screening program needs to be designed. The screening program needs to
optimize the benefits and minimize the harms of screening. Study I gave insight into
how PSA testing intervals are associated with these benefits and harms of screening and
the results can be used as one of the references to plan future personalized screening
programs to fit men on an individual basis. We showed that for men with PSA above
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1 ng/mL, testing with longer than annual intervals was associated with higher risk
of ISUP ≥ 2 prostate cancer. However, the benefit of an annual PSA testing interval
needs to be balanced against the increased risk of cumulative probability of a negative
biopsy, which was threefold with annual vs. triennial testing intervals. Even though the
screening program will possibly be implemented using a different screening test than
the PSA test (such as other available blood tests or prostate cancer risk calculators), all
of these include PSA and therefore our results are likely applicable to aid the design
of a screening program using any of those risk tools.
7.1.2 ISUP 1 Prostate Cancer and the PSA Test
ISUP 1 prostate cancer is the most common type of prostate cancer. It seldom becomes
metastatic and few men die from the disease. Studies have shown that screening men
with PSA increases overdiagnosis and overtreatment of prostate cancer [12] because
many healthy men are biopsied using PSA as a screening tool for prostate cancer. In
Study II we found that PSA was not associated with the diagnosis of ISUP 1 prostate
cancer, neither on an overall level nor on a biopsy core level. This evidence suggests
that prostate tissue with ISUP 1 prostate cancer behaves more like benign prostate cells
then ISUP ≥ 2 prostate cancer cells. Many believe that ISUP 1 prostate cancer should
not be labeled as cancer and alternatively it can be diagnosed as a type of pre-stage
of prostate cancer, keeping those men under surveillance [40]. As long as we only use
PSA as an unorganized screening tool for prostate cancer and biopsying healthy men,
the diagnosis of ISUP 1 cancers are likely to continue to substitute around half of all
diagnosed prostate cancers.
7.2 MRI and Risk Prediction Models
Recent studies have reported that incorporating MRI results into prostate cancer risk
prediction models has improved test characteristics compared to models only based
on clinical variables [80, 81, 82]. Our results for the unified S3M-MRI model in Study
III validated the results of these previous studies and added to them in two respects:
we used biomarker variables and a genetic score in addition to the clinical variables
and the multisite design of the study allowed validation of the risk model on entirely
independent data. However, these improvements in performance of the unified mod-
els have to be weighed against the increase in cost of sending all men with suspicion
of prostate cancer to MRI and the increase in complexity of the clinical workflow of
adding an extra risk prediction model subsequent to MRI examination. Therefore, we
also compared clinical outcomes of five diagnostic strategies, using different combi-
nations of the Stockholm3 test, MRI results and the S3M-MRI model. We found that
using the S3M-MRI model resulted in similar number of biopsies and diagnosed ISUP
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≥ 2 prostate cancers as using the Stockholm3 test and MRI sequentially. The latter
strategy resulted in 35% fewer MRI scans without meaningfully affecting the clinical
outcomes, thereby saving costs and simplifying workflows compared to MRI risk pre-
diction models.
A recent study by Siddiqui et al. showed that the use of prostate MRI can also lead to
more accurate classification of biopsy outcome compared to whole gland pathology
after prostatectomy [61]. The predictive ability of targeted biopsy for discriminating be-
tween ISUP 1 versus ISUP ≥ 2 prostate cancer on prostatectomy samples was greater
than that of standard biopsy with an AUC of 0.73 compared to AUC of 0.59 with
standard biopsy. Most current prostate cancer risk prediction models are trained on
systematic biopsy outcome that are to a large degree (30–60%) reclassified when com-
pared to whole gland pathology on radical prostatectomy samples. Thus, using MRI
and targeted biopsy results to develop new prostate cancer risk prediction models with
improved classification of ISUP grade can improve the predictive abilities of prostate
cancer risk prediction models.
7.3 Risk Tools for Prostate Cancer Diagnosis
Most prostate cancer risk tools have an AUC between 0.60 and 0.85 and they are very
dependent on the cohort we use due to selection bias. It is common that AUCs are
compared between different cohorts, but because of how dependent they are on the
type of patients in the cohort, it is almost impossible to compare and should in fact not
be done. If we want to compare different risk prediction models, we need to test them
on the same cohort of patients and then present our results as an external validation
of the risk tools. Another reason for the AUC being lower on average than in good
prediction models in other fields is that the outcome variable (systematic biopsy ISUP
grade) is to a large degree reclassified on whole gland pathology samples. Thus the
true disease status might be wrong in some cases and it is difficult to develop a perfectly
discriminating model. Also, PSA has in most studies been used as a pre-selection test
for inclusion. If men with low PSA would be included in the datasets for the models,
the AUC could improve since it is easier for the model to discriminate between men
with very low and very high PSA.
7.4 Limitations
One of the main limitations as well as one of the main strengths of this thesis is the
data sources we have used. In the case of the Stockholm3 test, the data set used to
develop and validate the model was very large in a clinical setting (n = 59.149 men)
using data from men 50–69 years old, of Northern European descent from Stockholm,
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Sweden. The model has shown to perform well when predicting the risk of high-grade
prostate cancer for Nordic men, both in the validation cohort of our study and in other
continued validation studies performed in Stockholm and Norway. To be able to con-
clude that the model is generalizable for the total population of older men it is an
extremely important next step to validate the model on external data using men of
different ethnic background, from different geographical areas in countries that have
different lifestyles from Swedish men.
Another limitation to this thesis includes a possible selection bias in the data. Tan-
gen et al. showed that known risk factors for prostate cancer increased the risk of
being biopsied in two large prostate cancer prevention trials that can lead to a possible
bias in their associations with prostate cancer risk [83]. Risk factors identified in epi-
demiological studies may be erroneous and can lead to misdirected study conclusions.
Because prostate cancer is highly prevalent in older men and it is usually asymptomatic
until metastatic, assumptions can be made on risk factors that possibly are not associ-
ated with prostate cancer. Respectively, men with that risk factor are more likely to be
screened for prostate cancer and subsequently those who screen positive for that risk
factor are more likely to be recommended and undergo biopsy. As a result, the men
with the risk factor are more likely to be diagnosed with prostate cancer. To counteract
this effect, the men in the Stockholm3 study were randomly invited to participate by
date of birth and men with high PSA, high Stockholm3 score or those at high risk for
prostate cancer in some other aspect were recommended to undergo biopsy.
One more limitation to this thesis is measurement bias in our data. Even though
registry data and the data we used from the STHLM3 study and Stockholm3-MRI
study are of high quality, classification problems in the biopsy outcome are common,
which is the outcome variable in all my four studies. Reclassifying the prostatectomy
sample with a higher grade than on the biopsy sample is more common than the op-
posite [43, 45], and thus the risk evaluation in my thesis might be biased towards a
lower risk level than the actual risk of prostate cancer. Also, in general we do not have
data on the final outcome (death from prostate cancer) and thus we are almost always
working with a proxy endpoint.
7.5 Ethical Concerns
Prediction models in a clinical setting can be a very useful tool, and as developers
of such powerful tools, we need to be careful to take ethical concerns seriously. It is
important to cover all areas of risk, to use the data we have carefully and validate our
models in external settings. These are among the most important aspects of developing
prediction models, especially when it includes and affects the health and lives of many
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people. We also need to ask the right questions in our models and when asking these
questions we need to be careful using sensitive information such as gender, race, age
and socioeconomic status. There are many examples of harmful risk prediction models
that result in discriminating decisions based on personal features. However, in the
case of prediction models within medicine we are hopefully always striving to improve
the health of individuals and these discriminating features can be important in our
model. As long as we deem the model unharmful and exclusively for the purpose of
improving the health of individuals, in my opinion it is the right ethical decision to use
discriminating features for the development of our models.
The use of population and health registers for research is governed by Swedish law,
and using register data under secrecy is allowed for research if the study has been ap-
proved by the regional ethics review board and if the register holder approves the data
extraction. All studies in this thesis had an ethical approval from the Ethical Review
Board in Stockholm. To ensure that the data is handled in a safe manner, registers
hold secure databases and safe IT environments and directly identifying information
such as name and personal identification number are removed and replaced with a
randomly generated id number.
Chapter 8
Future research
The field of prostate cancer diagnostics is currently moving very fast, and there is large
number of important research areas within prostate cancer diagnostics where new
studies are warranted (e.g. finding and evaluating new markers such as ctDNA, and
the use of AI for ISUP grading). I will briefly describe two future studies that I think
are key to the development:
8.1 Personalized Screening for Prostate Cancer
Organized screening for prostate cancer is in my opinion the next step in the health
care of middle aged men. Whether it will be using PSA only (currently very common
and unorganized) or using new risk tools, it is important to study the effect of different
screening intervals such as we did in Study 1. Since there has not been any organized
prostate cancer screening, there is no direct evidence of the long term effect of different
screening intervals on the diagnosis of prostate cancer or mortality rates of the patients
after diagnosis.
To study the effect of different screening intervals using risk prediction models, a
follow up study of the STHLM3 study is a very interesting option. Such a study can
contribute to the research of personalized screening for prostate cancer as well as pro-
vide important information on incidence and mortality rates of prostate cancer using
organized screening with a risk prediction model. The grand scale of the study cohort,
the use of a blood based risk prediction model and by randomly dividing the men into
different screening interval groups we could contribute to the design of an optimal
screening program for prostate cancer worldwide.
8.2 External Validation of the Stockholm3 and S3M-MRI
To make the Stockholm3 model and the S3M-MRI model applicable for clinical use,
an external validation of the models is necessary and extremely important. There are
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many factors that come into play when developing a clinical risk prediction model and
thus testing the model in other geographical areas, on men of a different ethnicity than
Northern-European descent and possibly even younger and older men is an important
next step in the validation of the Stockholm3 and the S3M-MRI prostate cancer risk
prediction models.
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